10x Genomics, Inc. (TXG) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

10x Genomics, Inc. (TXG) Healthcare & Pipeline Overview

10x Genomics, Inc. provides advanced tools for single cell and spatial biology, enabling researchers to explore biological systems at unprecedented resolution. The company's integrated solutions, including instruments, consumables, and software, serve the academic, biopharmaceutical, and biotechnology sectors, driving innovation in genomics research and drug discovery.

What Is the Investment Thesis for TXG?

10x Genomics holds a strong position in the rapidly growing market for single-cell and spatial biology analysis tools. The company's integrated solutions, combining instruments, consumables, and software, create a high barrier to entry and foster customer loyalty. With a gross margin of 69.6%, 10x Genomics demonstrates strong pricing power and operational efficiency. Key growth catalysts include the continued adoption of single-cell and spatial technologies in drug discovery and clinical research. However, the company's beta of 2.17 indicates high volatility, and a negative profit margin of -3.5% raises concerns about profitability. Investors should monitor the company's ability to achieve sustained profitability and manage its operating expenses. Continued innovation and expansion into new applications will be crucial for maintaining its competitive edge.

Based on FMP financials and quantitative analysis

TXG Key Highlights

Market capitalization of $7.90B reflects investor confidence in 10x Genomics' growth potential.

• Gross margin of 69.6% indicates strong pricing power and efficient cost management.
• Negative profit margin of -3.5% highlights the need for improved operational efficiency and cost control.
• Beta of 2.17 suggests high volatility compared to the broader market.
• Serves a diverse customer base including academic, government, biopharmaceutical, and biotechnology institutions.

Who Are TXG's Competitors?

TXG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TXG's Key Strengths?

Innovative technology platform for single-cell and spatial biology.

• Integrated solutions (instruments, consumables, software).
• Strong brand reputation and established customer base.
• High gross margin.

What Are TXG's Weaknesses?

Negative profit margin.

• High beta indicates significant volatility.
• Reliance on consumables revenue.
• Potential for competition from established players.

What Could Drive TXG Stock Higher?

Continued adoption of single-cell and spatial technologies in drug discovery and clinical research.

• Potential regulatory approvals for clinical applications of 10x Genomics' technology.
• Expansion of product portfolio with new assays and workflows.
• Strategic partnerships and collaborations to expand market reach.

What Are the Key Risks for TXG?

Negative return on equity (-9.3%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established players in the genomics and biotechnology industries.
• Technological obsolescence.
• Regulatory hurdles for clinical applications.
• Economic downturn impacting research budgets.
• Reliance on key personnel.

What Are the Growth Opportunities for TXG?

• Growth opportunity 1: Expanding into clinical applications represents a significant growth opportunity for 10x Genomics. As single-cell and spatial technologies become more widely adopted in clinical research and diagnostics, the company can leverage its existing platform to develop new assays and workflows for disease diagnosis, prognosis, and treatment monitoring.
• Growth opportunity 2: Geographic expansion, particularly in Asia-Pacific, offers another avenue for growth. The demand for advanced genomics research tools is increasing rapidly in countries like China and India, driven by growing investments in healthcare and biotechnology. 10x Genomics can capitalize on this trend by establishing a stronger presence in these markets through strategic partnerships, direct sales, and localized support.
• Growth opportunity 3: Developing new applications for its existing platform can drive incremental revenue growth. 10x Genomics can expand its product portfolio by developing new assays and workflows for emerging areas of biological research, such as microbiome analysis, drug screening, and synthetic biology. By continuously innovating and expanding its application offerings, the company can maintain its competitive edge and attract new customers.
• Growth opportunity 4: Leveraging strategic partnerships and collaborations can accelerate growth and expand market reach. 10x Genomics can partner with leading academic institutions, biopharmaceutical companies, and technology providers to develop new solutions, validate its technology, and access new markets. These partnerships can provide valuable resources, expertise, and market access, enabling the company to achieve its growth objectives more efficiently.
• Growth opportunity 5: Enhancing its software and data analytics capabilities can create a more compelling value proposition for customers. 10x Genomics can invest in developing advanced software tools for data analysis, visualization, and interpretation. By providing user-friendly and powerful software solutions, the company can help its customers extract more insights from their single-cell and spatial data, driving adoption and increasing customer loyalty.

What Are TXG's Competitive Advantages?

• Proprietary microfluidics technology creates a barrier to entry.
• Integrated solutions (instruments, consumables, software) enhance customer loyalty.
• Strong brand reputation and established customer base.
• Extensive patent portfolio protects its core technology.

What Does TXG Do?

10x Genomics, Inc., founded in 2012 and headquartered in Pleasanton, California, is a life science technology company focused on developing and commercializing innovative solutions for biological analysis. Originally named 10X Technologies, Inc., the company rebranded in November 2014 to reflect its focus on genomics. 10x Genomics provides instruments, consumables, and software that enable researchers to analyze biological systems at a previously unattainable resolution. Its primary offerings include the Chromium and Chromium Connect instruments, which are used in conjunction with microfluidic chips, slides, reagents, and other consumables. These tools support single-cell gene expression, single-cell immune profiling, single-cell ATAC, and single-cell multiome ATAC + gene expression. The company's Visium spatial gene expression solution allows for the measurement of spatial gene expression patterns across tissue samples, and can be combined with immunofluorescence for gene expression and protein co-detection. 10x Genomics serves a diverse customer base, including academic institutions, government laboratories, biopharmaceutical companies, and biotechnology firms across North America, Europe, the Middle East, Africa, China, and the Asia Pacific region. By providing comprehensive solutions for single-cell and spatial biology, 10x Genomics is a key enabler of advancements in genomics research and drug discovery.

What Products and Services Does TXG Offer?

• Develops and sells instruments for analyzing biological systems.
• Provides consumables such as microfluidic chips and reagents.
• Offers software solutions for data analysis and visualization.
• Enables single-cell gene expression analysis.
• Supports single-cell immune profiling.
• Facilitates spatial gene expression analysis.
• Serves academic, government, and biopharmaceutical institutions.

How Does TXG Make Money?

• Sells instruments (Chromium, Chromium Connect) to research institutions and companies.
• Generates recurring revenue through the sale of consumables (chips, reagents).
• Offers software licenses for data analysis and visualization.
• Provides service and support contracts for its instruments.

What Industry Does TXG Operate In?

The healthcare information services industry is experiencing rapid growth, driven by advancements in genomics, proteomics, and other areas of biological research. 10x Genomics is positioned within this industry as a key provider of tools for single-cell and spatial biology analysis. The market is competitive, with companies like Illumina and Bio-Rad offering competing solutions. However, 10x Genomics' integrated approach, combining instruments, consumables, and software, provides a differentiated value proposition. The increasing demand for personalized medicine and targeted therapies is fueling the adoption of single-cell and spatial technologies, creating significant growth opportunities for 10x Genomics.

Who Are TXG's Key Customers?

• Academic research institutions
• Government laboratories
• Biopharmaceutical companies
• Biotechnology firms

10x Genomics, Inc. Financial Trajectory

10x Genomics, Inc. (TXG) reported $151.0M in revenue for Q2 2026, reflecting 0.1% growth compared to the prior quarter. The company recorded a net loss of $17.9M, with diluted EPS of $-0.14. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, TXG averaged $-0.15 in diluted EPS.

Company Profile

10x Genomics, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Pleasanton, US. The company is led by CEO Serge Saxonov. TXG has traded publicly since 2019.

How 10x Genomics, Inc. Is Valued

10x Genomics, Inc. carries a market capitalization of $7.90B, placing it in the mid-cap category. Relative to its peer group, TXG's quantitative score of 38/100 is below the peer average of 79/100.

Return on equity for 10x Genomics, Inc. stands at -9.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -7.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.69 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.9%, the inverse of the P/E and a quick read on earnings relative to price.

10x Genomics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 19.84 places it in the safe zone, indicating low near-term bankruptcy risk.

10x Genomics, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 12.4% above estimates on average.

Wall Street analysts project 10x Genomics, Inc. revenue of about $613.7M for fiscal 2026, with EPS near $-0.81. The estimate reflects 12 contributing analysts.

TXG Financials

TXG Latest News

TXG Analyst Consensus

TXG MoonshotScore

Latest 10x Genomics, Inc. Analysis

What Investors Ask About 10x Genomics, Inc. (TXG) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources